// App-Quantinova.ai

POS0527 (2022) : ANTI-CCP POSITIVE INDIVIDUALS AT RISK OF PROGRESSION TO INFLAMMATORY ARTHRITIS: WHAT HAPPENS TO BIOMARKERS PRIOR TO PROGRESSION?

Researchers

Presenter

  • L. Duquenne

Principal Investigators

  • K. Harnden

  • L. Garcia-Montoya

  • N. Sidhu

  • J. Nam

  • K. Mankia

  • P. Emery

Medical Centers

  • University of Leeds, Leeds Institue of Rheumatic and Musculoskeletal Medicine, Leeds, United Kingdom

  • Leeds Biomedical Research Centre, NIHR, Leeds, United Kingdom

Locations

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Autoimmune (AI)

Disease

  • Inflammatory Arthritis

Biomarkers

  • anti-CCP antibodies

  • Estrogen receptor alpha

Drug/Treatment

  • N/A

Outcome

  • N/A

Study Design

  • Observational

  • Prospective

  • Cohort

  • Single Center

Phase

  • N/A

Study Id's

  • N/A

Sponsors

  • Gilead Sciences Inc

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved